[液体活检在伴有恶性胸腔积液的肺癌诊断与治疗中的进展]
[Progress of Liquid Biopsy in the Diagnosis and Treatment of Lung Cancer with Malignant Pleural Effusion].
作者信息
Zeng Hao, Tian Panwen, Li Weimin
机构信息
Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2021 Sep 20;24(9):653-659. doi: 10.3779/j.issn.1009-3419.2021.101.24. Epub 2021 Jul 14.
Lung cancer is the malignancy with the highest mortality rate worldwide. Malignant pleural effusion (MPE) caused by advanced lung cancer severely affects the quality of life and prognosis of patients. Tumor-associated genetic testing is the basis for making precise treatment decisions. There are some risks of tissue biopsy, and it is difficult to sample repeatedly. Due to its non-invasive and can reflect the full profile of tumor gene characteristics, liquid biopsy is increasingly used in the diagnosis and treatment of lung cancer. Because of the extremely low DNA level of circulating tumor, the sensitivity and specificity of liquid biopsy based on blood samples are limited. Tumor cells is enriched in MPE. The detection of cell-free DNA, extracellular vesicles and microRNA in MPE will be helpful to the diagnose, treatment and assess prognosis of patients with lung cancer. This review aims to discuss the research progress of liquid biopsy based on MPE in the diagnosis and treatment of lung cancer patients. .
肺癌是全球死亡率最高的恶性肿瘤。晚期肺癌所致恶性胸腔积液（MPE）严重影响患者生活质量和预后。肿瘤相关基因检测是做出精准治疗决策的基础。组织活检存在一定风险，且难以重复取样。液体活检因其具有非侵入性且能反映肿瘤基因特征全貌，在肺癌诊疗中应用日益广泛。由于循环肿瘤DNA水平极低，基于血样的液体活检的敏感性和特异性受限。肿瘤细胞在MPE中富集。检测MPE中的游离DNA、细胞外囊泡和微小RNA将有助于肺癌患者的诊断、治疗及预后评估。本综述旨在探讨基于MPE的液体活检在肺癌患者诊疗中的研究进展。
Zotero 插件